Antibiotic resistance of ocular surface flora with repeated use of a topical antibiotic after intravitreal injection

JAMA Ophthalmology

Volumn 131, Issue 4, 2013, Pages 456-461

  Yin, Vivian T ^a   Weisbrod, Daniel J ^a   Eng, Kenneth T ^a   Schwartz, Carol ^a   Kohly, Radha ^a   Mandelcorn, Efrem ^c   Lam, Wai Ching ^c   Daneman, Nick ^b   Simor, Andrew ^b   Kertes, Peter J ^a,c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b Departments of Medicine and Microbiology   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; MOXIFLOXACIN; RANIBIZUMAB;

ABSENCE OF SIDE EFFECTS; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; ENDOPHTHALMITIS; FEMALE; FLORA; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULA AGE RELATED DEGENERATION; TOPICAL TREATMENT;

ADMINISTRATION, TOPICAL; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; ANTIBODIES, MONOCLONAL, HUMANIZED; AZA COMPOUNDS; BACTERIA; CEFTAZIDIME; COHORT STUDIES; CONJUNCTIVA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENDOPHTHALMITIS; FEMALE; HOSPITALS, TEACHING; HUMANS; INTRAVITREAL INJECTIONS; MALE; MICROBIAL SENSITIVITY TESTS; PROSPECTIVE STUDIES; QUINOLINES; WET MACULAR DEGENERATION;

EID: 84876257480     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2013.2379     Document Type: Article

References (40)

1. Campbell RJ, Bronskill SE, Bell CM, Paterson JM, Whitehead M, Gill SS. Rapid expansion of intravitreal drug injection procedures, 2000 to 2008: a population-based analysis. Arch Ophthalmol. 2010;128(3):359-362.
2. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355 (14):1419-1431.
3. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444.
4. Elman MJ, Aiello LP, Beck RW, et al; Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010; 117(6):1064-1077.
5. Mitchell P, Bandello F, Schmidt-Erfurth U, et al; RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615-625.
6. Campochiaro PA, Heier JS, Feiner L, et al; BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1102-1112.
7. Brown DM, Campochiaro PA, Singh RP, et al; CRUISE Investigators. Ranibi-zumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1124-1133.
8. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: a comprehensive review. Retina. 2004;24(5):676-698.
9. Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina. 2008;28(10): 1395-1399.
10. Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol. 2008;145(5):879-882.
11. Bhavsar AR, Ip MS, Glassman AR; DRCRnet and the SCORE Study Groups. The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol. 2007;144(3):454-456.
12. McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina. 2011;31(4):654-661.
13. Kresloff MS, Castellarin AA, Zarbin MA. Endophthalmitis. Surv Ophthalmol. 1998; 43(3):193-224.
14. Alabiad CR, Miller D, Schiffman JC, Davis JL. Antimicrobial resistance profiles of ocular and nasal flora in patients undergoing intravitreal injections. Am J Ophthalmol. 2011;152(6):999-1004.
15. Moss JM, Sanislo SR, Ta CN. A prospective randomized evaluation of topical gatifloxacin on conjunctival flora in patients undergoing intravitreal injections. Ophthalmology. 2009;116(8):1498-1501.
16. Kim SJ, Toma HS. Antimicrobial resistance and ophthalmic antibiotics: 1-year results of a longitudinal controlled study of patients undergoing intravitreal injections. Arch Ophthalmol. 2011;129(9):1180-1188.
17. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Second Informational Supplement, M100-S22. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
18. Park SH, Lim JA, Choi JS, Kim KA, Joo CK. The resistance patterns of normal ocular bacterial flora to 4 fluoroquinolone antibiotics. Cornea. 2009;28(1): 68-72.
19. Betanzos-Cabrera G, Juárez-Verdayes MA, González- González G, Cancino-Díaz ME, Cancino-Díaz JC. Gatifloxacin, moxifloxacin, and balofloxacin resistance due to mutations in the gyrA and parC genes of Staphylococcus epidermidis strains isolated from patients with endophthalmitis, corneal ulcers and conjunctivitis. Ophthalmic Res. 2009;42(1):43-48.
20. Miño de Kaspar H, Koss MJ, He L, Blumenkranz MS, Ta CN. Antibiotic susceptibility of preoperative normal conjunctival bacteria. Am J Ophthalmol. 2005; 139(4):730-733.
21. Chung JL, Seo KY, Yong DE, et al. Antibiotic susceptibility of conjunctival bacterial isolates from refractive surgery patients. Ophthalmology. 2009;116(6): 1067-1074.
22. Speaker MG, Menikoff JA. Prophylaxis of endophthalmitis with topical povidone-iodine. Ophthalmology. 1991;98(12):1769-1775.
23. Apt L, Isenberg SJ, Yoshimori R, Paez JH. Chemical preparation of the eye in ophthalmic surgery, III: effect of povidone-iodine on the conjunctiva. Arch Ophthalmol. 1984;102(5):728-729.
24. Isenberg SJ, Apt L, Yoshimori R, Khwarg S. Chemical preparation of the eye in ophthalmic surgery, IV: comparison of povidone-iodine on the conjunctiva with a prophylactic antibiotic. Arch Ophthalmol. 1985;103(9):1340-1342.
25. Safar A, Dellimore MC. The effect of povidone iodine flush versus drops on con-junctival colonization before intravitreal injections. Int Ophthalmol. 2007;27 (5):307-312.
26. Ta CN, Egbert PR, Singh K, Shriver EM, Blumenkranz MS, Miño De Kaspar H. Prospective randomized comparison of 3-day versus 1-hour preoperative ofloxa-cin prophylaxis for cataract surgery. Ophthalmology. 2002;109(11):2036- 2041.
27. Callegan MC, Novosad BD, Ramadan RT, Wiskur B, Moyer AL. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones. Adv Ther. 2009;26(4):447-454.
28. Bannerman TL, Rhoden DL, McAllister SK, Miller JM, Wilson LA. The source of coagulase-negative staphylococci in the Endophthalmitis Vitrectomy Study: a comparison of eyelid and intraocular isolates using pulsed-field gel electrophoresis. Arch Ophthalmol. 1997;115(3):357-361.
29. Speaker MG, Milch FA, Shah MK, Eisner W, Kreiswirth BN. Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis. Ophthalmology. 1991;98(5):639-650.
30. Simunovic MP, Rush RB, Hunyor AP, Chang AA. Endophthalmitis following in-travitreal injection versus endophthalmitis following cataract surgery: clinical features, causative organisms and post-treatment outcomes. Br J Ophthalmol. 2012; 96(6):862-866.
31. Bhavsar AR, Googe JM Jr, Stockdale CR, et al; Diabetic Retinopathy Clinical Research Network. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the Diabetic Retinopathy Clinical Research Network laser-ranibizumab-triamcinolone clinical trials. Arch Ophthalmol. 2009; 127(12):1581-1583.
32. Bhatt SS, Stepien KE, Joshi K. Prophylactic antibiotic use after intravitreal injection: effect on endophthalmitis rate. Retina. 2011;31(10):2032-2036.
33. Leaming DV; American Society of Cataract and Refractive Surgery. Practice styles and preferences of ASCRS members: 2000 survey. J Cataract Refract Surg. 2001; 27(6):948-955.
34. Graves A, Henry M, O'Brien TP, Hwang DG, Van Buskirk A, Trousdale MD. In vitro susceptibilities of bacterial ocular isolates to fluoroquinolones. Cornea. 2001; 20(3):301-305.
35. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology. 1999;106(7):1313-1318.
36. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology. 2000; 107(8):1497-1502.
37. Hwang DG. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. Surv Ophthalmol. 2004;49(suppl 2) :S79-S83.
38. Moss JM, Sanislo SR, Ta CN. Antibiotic susceptibility patterns of ocular bacterial flora in patients undergoing intravitreal injections. Ophthalmology. 2010; 117(11):2141-2145.
39. Mullin GS, Rubinfeld RS. The antibacterial activity of topical anesthetics. Cornea. 1997;16(6):662-665.
40. Kang SW, Lee JH. Antibacterial effect of tetracaine hydrochloride (Pontocaine) in the aspect of exposure time: in vitro study. Korean J Ophthalmol. 1989;3: 11-13.